Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim in Adult ITP
NCT00508820Phase 3Completed
- Sponsor
- Amgen
- Start
- Feb 2005
- Primary completion
- Jan 2011
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of romiplostim in immune thrombocytopenic purpura (ITP), sponsored by Amgen. Primary endpoint: Adverse Events up to 205 weeks. Started Feb 2005; status: completed.
02
Drugs
romiplostim
03
Conditions
immune thrombocytopenic purpura (ITP)
Beyond the preview
Go deeper on NCT00508820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00508820.